Total GIP NL-ELISA for specific determination of glucose-dependent insulinotropic peptide in human samples
Total GIP NL-ELISA for specific determination of glucose-dependent insulinotropic peptide in human samples
Uppsala 19-09-02. The immunoassay company Mercodia is launching a new assay for quantitative detection of glucose-dependent insulinotropic peptide (GIP) in human samples, to be used by researchers and labs in the fields of metabolic disease. This easy-to-use, high-quality ELISA complements the company’s portfolio, so that all incretin hormones (insulin-stimulating factors) can be measured with Mercodia assays.
An assay for measuring GIP must be highly sensitive, with a wide range, as GIP circulates at low concentrations (5-20 pmol/L in healthy Caucasians) but increases postprandially and can be tripled after bariatric surgery. As limited amounts of valuable sample materials are a common challenge for researchers, it is important that an assay requires low sample volumes. GIP in the circulation is quickly degraded by the enzyme DPP-4, so that the majority of circulating GIP
“Our R&D department has worked really hard on these issues, to solve all the problems that researchers can encounter when trying to measure GIP properly. We chose to develop a total GIP ELISA, that measures both full-length bioactive GIP(1-42) and GIP(3-42), to provide a complete overview of secreted GIP,” explains Hanna Ritzén, Managing Director Research and Development at Mercodia.
The Mercodia Total GLP-1 NL-ELISA requires only 25 μL of sample volume, which allows repeated sampling at multiple time points and/or quantification of more biomarkers in the same precious sample material. This new assay is the third in the Mercodia Northern Lights product line.
“These products employ chemiluminescence as the method for detection. This sensitive detection makes it possible to push the measuring range to very low concentrations, which allows the Total GIP-1 NL-ELISA to detect levels from 2.7 to 1,000 pmol/L with high precision,” Hanna Ritzén concludes.
Learn more about the Mercodia Total GIP NL-ELISA here.
About Mercodia
Mercodia is a world-leading developer, manufacturer and distributor of high quality immunoassays in the areas of diabetes, obesity and cardiovascular disease. We offer assays and services applicable to both human and animal models. We service a global market of over 100 countries with immunoassays spanning nine different species, covering basic, preclinical and clinical research sectors. Read more at www.mercodia.com
Editorial follow-up
Lisa Grufman, Marketing Manager
+46707809506
